Merrion Pharmaceuticals and Novo Nordisk have signed a collaboration and option agreement to evaluate the ability of Merrion’s GIPET technology to boost the oral bioavailability of an undisclosed compound. Following the feasibility studies, Novo Nordisk will have the option to license Merrion’s GIPET technology. As part of the agreement, Merrion has granted Novo Nordisk a warrant to acquire as much as $2 million of Merrion shares. The warrant is valid for 20 business days followin...